Moreover, combination benefit is observed in in vitro native cell lines as well as in trametinib-resistant models and in vivo cell line and patient-derived tumor xenografts treated with the combination of clinical grade small molecule inhibitors of C/BRAF and MEK. The gene discussed is BRAF; the disease is neoplasm.